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Introduction: Oncogenic ALK kinase activity associated with 
ALK gene rearrangement is the target of crizotinib, an ALK inhibi-
tor recently approved by the Food and Drug Administration for the 
treatment of ALK-rearranged (ALK+) non–small cell lung cancers. 
ALK+ status is generally thought to be mutually exclusive of epider-
mal growth factor receptor (EGFR) and KRAS mutations. However, 
the mutation status of other genes is not widely known in ALK+ 
tumors. The aim of this study is to survey for mutations involv-
ing other genes in 25 ALK+ cases confirmed by fluorescent in situ 
hybridization.
Methods: Using the DNA extracted from formalin-fixed paraf-
fin-embedded tumor samples, a MassArray-based Lung Cancer 
Mutations Screening Panel was performed to test for 179 individ-
ual mutations in 10 genes, including EGFR, KRAS, BRAF, ERBB2, 
JAK2, AKT1, AKT2, KIT, MET and PIK3CA, which have been impli-
cated in lung carcinogenesis and/or considered as potential therapeu-
tic targets.
Results: Five of 25 ALK+ cases showed additional genetic abnor-
malities, which were verified by gene sequencing. One patient had 
EGFR del L747-S752. The remaining four mutations were in the 
MET gene: MET N375S (n = 2) and MET R988C (n = 2). No MET 
amplification was found by fluorescent in situ hybridization in the 
four cases with MET mutation. No mutations were detected in the 
other genes tested.
Conclusions: In summary, additional mutations were found in 20% 
of ALK+ cases involving two of the 10 genes tested. Our study high-
lights that EGFR mutation can be present in ALK+ tumors, though 
uncommon. Clinical implication of MET mutation in our cases is 
uncertain and further study is needed.
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Approximately 5% of lung adenocarcinomas have a chro-mosomal rearrangement that generates a fusion gene 
between echinoderm microtubule-associated protein-like 
4 (EML4) and anaplastic lymphoma kinase (ALK).1–3 The 
EML4–ALK fusion results in constitutive ALK kinase activ-
ity, which is thought to drive carcinogenesis in this subset of 
tumors.2,4 Tumors with ALK rearrangements (ALK+) have a 
higher prevalence in patients with certain demographic fea-
tures, including never, light or former smoking status and 
younger age.3,5,6 ALK rearrangements are most common 
in tumors with adenocarcinoma histology, although rare 
examples of adenosquamous or squamous cell carcinoma 
harboring ALK mutations have been reported.5,7,8 Certain 
histomorphologic features have also been associated with 
ALK rearrangement, including signet ring cell features 
and tumors with a cribriform and mucinous phenotype, 
although more common patterns, including papillary, aci-
nar, and lepidic, have been described in tumors with ALK 
mutations.1,3,8,9 Testing for ALK rearrangements has become 
increasingly important in non–small-cell lung carcinoma 
(NSCLC), given the approval of the ALK kinase inhibitor 
crizotinib for ALK+ tumors.10,11
Early studies showed ALK rearrangement to be mutually 
exclusive of EGFR and KRAS mutations, which are the other 
relatively high-prevalence mutations that have been described 
in NSCLC to date.1,5,12 Testing for EGFR mutation has become 
routine in the management of NSCLC, given the availability 
of effective EGFR kinase inhibitors for treatment of tumors 
with EGFR mutations.13–15 EGFR mutations are seen in higher 
frequency in lung adenocarcinomas, occurring in never 
smokers and people of Asian ethnicity, with the prevalence 
ranging from 10% to 50% depending on these factors.14,16–18 
KRAS mutation testing is also relatively common, because 
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it has high prevalence (20%–30%) in lung adenocarcinomas 
affecting western patients with smoking history. Tumors with 
KRAS mutations do not harbor EGFR mutations and will not 
respond to EGFR-inhibitor therapy.13,19,20 Although initial 
studies showed ALK+ cases to be wild-type for EGFR and 
KRAS, examples of tumors harboring mutations in both ALK 
and EGFR or KRAS have been reported in the literature.5,12,21–24 
These have been published mostly as case reports or single 
events, which preclude accurate assessment of incidence, 
but these double mutants seem to be quite rare. This creates 
a challenge when deciding on appropriate testing algorithms, 
that is, whether to test all patients for all mutations or stop 
testing as soon as one mutation is found.
Because little improvement has been made in the very 
poor prognosis of lung carcinoma of the last 50 years, the iden-
tification of these potentially targetable kinase mutations has 
been a very exciting advancement in lung cancer treatment. 
Although the mutations driving many lung carcinomas remain 
unknown, approximately 50% of lung adenocarcinoma cases 
harbor KRAS mutation, EGFR mutation, or ALK translocation, 
and an additional 5% or so has been shown to have a muta-
tion involving BRAF, PIK3CA, HER2, MET, MEK1, NRAS, or 
AKT.25 In the vast majority, these driver mutations are mutu-
ally exclusive, although rare examples of double mutants have 
been reported.5,12,21–24 It has been well recognized that many 
patients treated with Food and Drug Administration–approved 
EGFR tyrosine kinase inhibitors develop acquired resistance. 
Putative mechanisms of resistance to EGFR tyrosine kinase 
inhibitor include restoration of EGFR signaling by T790M 
mutation or EGFR amplification, and restoration of signaling 
downstream of EGFR through MET amplification or PIK3CA 
mutations.26 Similarly, it is expected that the patients with 
ALK+ adenocarcinomas would also develop crizotinib resis-
tance eventually,27 and indeed, series of patients with acquired 
crizotinib resistance have been reported.24,28
Although many studies have looked for the presence of 
EGFR and KRAS mutations and copy number alterations in 
small numbers of ALK+ tumors, the mutation status of other 
driver genes in crizotinib-naive ALK+ lung adenocarcinoma is 
not widely known. The purpose of the present study is to sur-
vey a group of ALK-rearranged tumors for KRAS and EGFR 
mutations, and mutations in other oncogenes that have been 
implicated in carcinogenesis or may be a potential therapeutic 
target. We believe that this information will be useful in over-
coming crizotinib resistance.
MATERIALS AND METHODS
The protocol for this study was approved by the Mayo 
Clinic Institutional Review Board. Twenty-five cases of pul-
monary adenocarcinoma surgically treated at Mayo Clinic 
(1999–2007) with ALK gene rearrangement, confirmed by 
break-apart fluorescent in situ hybridization (FISH) and 
immunohistochemistry (IHC), were selected for additional 
genetic testing. The original screening cohort was enriched for 
nonsmokers to increase the yield of ALK+ cases, but the muta-
tion status of all genes tested in this study was unknown at the 
time of screening. FISH and immunostaining methods were 
performed as previously described.6,7,29 IHC was reported as 
positive if at least 10% of tumor cells showed positivity using 
the ALK-1 monoclonal antibody (Dako, Carpinteria, CA) and 
was semiquantitatively scored as 3+ (intense, granular cyto-
plasmic staining), 2+, (moderate, smooth cytoplasmic stain-
ing), 1+ (faint cytoplasmic staining), and 0 (negative). FISH 
was performed by applying a dual-color break-apart probe 
(Vysis, Abbott Molecular, Abbott Park, IL) and was consid-
ered positive if 15% or more of 100 counted cells showed 
break-apart of the red and green signals flanking the ALK 
locus or isolated red signals.
DNA was extracted from formalin-fixed paraffin-
embedded (FFPE) samples of macrodissected tumor speci-
mens or adjacent normal lung. In brief, the unstained FFPE 
tissues were sectioned to 10-μm thickness and deparaffinized 
using xylene. After the ethanol series, DNA was extracted 
with the AllPrep DNA/RNA FFPE kit (Qiagen Inc., Valencia, 
CA) following manufacturer’s protocol. Samples were run on 
MassArray (Sequenom, San Diego, CA)-based Lung Cancer 
Mutations Screening Panel (LuCaMSP), which tests for 187 
individual mutations in 10 genes, including EGFR, KRAS, 
BRAF, ERBB2, JAK2, AKT1, AKT2, KIT, MET, and PIK3CA. 
In brief, 20 ng of DNA from each case was amplified, using 
the LuCaMSP polymerase chain reaction (PCR) primer pools. 
The amplicons were treated with shrimp alkaline phosphatase 
followed by a single base extension reaction, using extension 
primer pools and Thermosequenase (Sequenom, San Diego, 
CA). Salts were removed with a cation exchange resin, and 
the DNA was spotted onto SpectroChipII. The principle of 
the MassArray-based LuCaMSP assay is to simultaneously 
survey common oncogene mutations based on the molecular 
mass differences of the single base-extended primers that are 
specific for each targeting gene mutations by mass spectrom-
etry.30 Data analysis was performed using MassArray Typer 
Analyzer 4.0 software (Sequenom). All individual calls were 
calculated based on peak height at the expected molecular 
weight and then manually reviewed. A peak ratio of 5% or 
more between the mutant and the wild-type alleles was con-
sidered as positive. All positive results were confirmed by 
Sanger sequencing. In the case with both ALK rearrange-
ment and EGFR mutation, reverse-transcriptase PCR was 
performed using the available fresh frozen tumor tissue. For 
complementary DNA (cDNA) synthesis, 100 ng of total RNA 
was generated using oligo(dT) primer followed by the manu-
facturer’s protocol (Invitrogen, Grand Island, NY), and cDNA 
was diluted 1:10 with RNAase-free water. cDNA was used as 
templates in PCR to detect potential EML4–ALK fusion prod-
ucts using exon 2 or 13 of EML4 as forward primer and exon 
20 of ALK as reverse primer. The resulting PCR product was 
subjected to Sanger sequencing to determine the exact fusion 
junction points for EML4–ALK.
To investigate MET amplification status, dual-color 
FISH was performed, using a custom-designed MET/CEP7 
probe (RP11-114O6 and RP11-1018C18 bacterial artificial 
chromosome clones) labeled with SpectrumOrange (Abbott 
Molecular) and centromeric chromosome 7 SpectrumGreen 
CEP7 DNA probe (Abbott Molecular) on 5-µm thick histological 
sections. In brief, FISH protocol consisted of deparaffination, 
retrieval in citrate buffer 10 mM pH 6.0, 40 minutes digestion at 
37°C with DigestAll (Invitrogen), dehydration, codenaturation 
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with the probe cocktail at 80°C for 5 minutes, followed 
by overnight hybridization at 37°C, stringent rinsing with 
0.1% nonidet P40 2× sodium chloride sodium citrate buffer, 
followed by 4′,6-diamidino-2-phenylindole dihydrochloride 
counterstaining. In each case, red MET signals and green 
CEP7 signals were enumerated in 100 adenocarcinoma 
cells (distributed in five different tumoral areas), using 
epifluorescence microscopy equipped with band pass filters 
fitting SpectrumOrange, SpectrumGreen and 4′,6-diamidino-2-
phenylindole dihydrochloride. Documentation was performed 
using CytoVision software (Genetix, Sunnyvale, CA). For each 
case, the mean and SD of MET and CEP7 number of signals 
per cell (mean copy number per cell), and the MET/CEP7 ratio 
were calculated (mean MET copy number per cell/mean CEP7 
copy number per cell). MET amplification was considered 
present when MET/CEP7 ratio was 2 or more.
RESULTS
Demographic and clinical features of the 25 patients 
included in this study are summarized in Table 1. There was 
roughly an equal number of men and women. Most patients 
were Caucasian (92%), with a mean age of 61 years. The 
original screening cohort was enriched for nonsmokers, and 
subsequently, the majority of patients (80%) studied here 
were never smokers. Most patients were stage I (44%), as was 
expected for surgically treated disease.
All 25 adenocarcinomas (100%) included in this study 
showed break-apart of the hybridization probes flanking the 
ALK gene by FISH. ALK IHC was scored in each case and 
showed the following results: ALK IHC score 1 in two cases 
(8%), score 2 in five cases (20%), and score 3 in 18 cases 
(72%).
Of the 25 ALK-rearranged cases, five patients (20%) 
showed additional genetic abnormalities based on the muta-
tion screen that were confirmed by sequencing (Table 2). One 
patient (4%) had EGFR del L747-S752 (Fig. 1). This patient 
showed ALK IHC score 1+, and a FISH pattern of isolated 
red signals in 43% of cells, split red and green signals in 3%, 
and isolated green signals in 2%. To better characterize this 
case, reverse-transcriptase PCR followed by sequencing of the 
EML4–ALK fusion break point was performed. Three sepa-
rate fusions were found, corresponding to variants 1, 3a, and 
3b (3a was the major fusion product).31 All EML4–ALK tran-
scripts were generated by either exon 13 (variant 1) or exon 
6 (variant 3a) of EML4 to exon 20 of ALK. The variant 3b 
fusion transcript sequence showed an additional 33-base pair 
sequence derived from intron 6 of EML4 gene (Fig. 1F).
The other four mutations (16% of ALK+ cases) were in 
the MET gene: two with MET N375S (Fig. 2) and the remaining 
two with MET R988C (Fig. 3). All four of these patients with 
MET mutations showed ALK IHC score of 3+. Testing of 
the normal appearing lung adjacent to the tumor showed the 
identical MET mutations, indicating that they likely represent 
germline changes. It is interesting that one patient was found 
to have a JAK2 V617F mutation at low mutation frequency 
(7%) by the LuCaMSP mutation screen assay (not detected by 
Sanger sequencing). Upon medical history review, this patient 
was found to have essential thrombocythemia, with JAK2 
V617F confirmed in the peripheral blood. No other mutations 
were found in any of the other genes tested.
We evaluated 12 cases for MET amplification by FISH, 
including the four cases that showed MET mutation and the 
one case with EGFR mutation. Mean MET copy number per 
cell varied between 1.80 and 5.49 (SD, ±0.54 to ±6.82), and 
mean CEP7 copy number per cell ranged between 1.78 and 
4.75 (SD, ±0.53 to ±5.41). MET/CEP7 ratio ranged between 
0.97 and 1.15; none of the 12 cases had MET amplification 
when the cases were considered as a whole. One case dis-
played a small subset of neoplastic cells (4%) with MET/
TABLE 1.  Demographic and Clinical Data for 25 
Patients with Pulmonary Adenocarcinoma Showing ALK 
Rearrangement
Total (n = 25)
Age at diagnosis
 Mean (SD) 61 (13.5)
 Range (36–87)
Sex
 Female 13 (52%)
 Male 12 (48%)
Race
 Caucasian 23 (92%)
 African American 1 (4%)
 Unknown 1 (4%)
Smoking status
 Never 20 (80%)
 Former 4 (16%)
 Current 1 (4%)
Grade
 Well differentiated 6 (24%)
 Moderately differentiated 14 (56%)
 Poorly/undifferentiated 5 (20%)
Stage
 I 11 (44%)
 II 2 (8%)
 III 6 (24%)
 IV 6 (24%)
Treatment modality
 Only surgery 12 (48%)
 Surgery and chemo/radiation 11 (44%)
 Unknown 2 (8%)
TABLE 2.  Summary of Five Cases with ALK Rearrangement 
and Other Coexisting Mutations
Age, yr Sex Race Mutation ALK 
Staining
Smoking 
Status
Stage
72 F Caucasian EGFR del 
L747-S752
1+ Never III
41 F Caucasian MET N375S 3+ Never IV
87 M Caucasian MET N375S 3+ Former I
52 F Caucasian MET R988C 3+ Never III
66 M Caucasian MET R988C 3+ Never II
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CEP7 ratio = 3.04, consistent with amplification of MET in 
this subpopulation, but this case did not show mutation in 
either MET or EGFR.
DISCUSSION
MET mutations were found in four of 25 ALK+ cases, 
and an EGFR mutation was identified in one additional ALK+ 
case. Although the clinical implication of MET mutations is 
uncertain, our results highlight that EGFR mutation can be 
present in ALK+ tumors, although uncommon. Our case is 
interesting in that it shows three separate EML4–ALK fusion 
genes in the same tumor, in conjunction with EGFR del 
L747-S752. Although variants 1, 3a, and 3b have all been 
described in ALK IHC-positive tumors,32 the heterogeneity in 
the fusion gene product may explain why the ALK IHC was 
only 1+ in this case.
Rare cases of coexisting EGFR and ALK mutations have 
been documented in the literature.5,12,21–24 The true incidence is 
unknown, because cases have only been described as a single 
occurrence in a series of NSCLC tested for ALK and EGFR, 
or in case reports. Our study, which has the largest number of 
ALK+ cases, showed one of 25 ALK+ cases (4%), that also had 
an EGFR exon 19 deletion. When screening 103 NSCLC for 
ALK mutations, Zhang et al.5 found one of 12 ALK+ cases (8%) 
FIGURE 1.  Pulmonary adenocar-
cinoma (A, hematoxylin and eosin 
stain; original magnification, 200×) 
with acinar and micropapillary 
growth, showing EGFR del L747-S752 
by LuCaMSP (B) confirmed by 
sequencing (C). The tumor shows 1+ 
ALK staining by immunohistochemis-
try (D). Fluorescent in situ hybridiza-
tion (FISH, E) shows a combination 
of two positive patterns: break-apart 
of the probes flanking the ALK locus 
by FISH (arrow), and one fusion with 
an isolated red signal (arrowhead). 
Sanger sequencing confirmed the 
presence of three EML4–ALK tran-
scripts (F), with exon 13 (variant 1) 
or exon 6 (variant 3a/b) of EML4 
fused to exon 20 of ALK.
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to contain coexisting EGFR exon 19 deletion. This compares to 
a screen of 305 NSCLC by Koivunen et al.12 which found eight 
ALK+ cases, one of which had coexisting EGFR exon 19 dele-
tion (12%). Although all these studies are limited by a low num-
ber of ALK+ cases, it seems that these double mutants are rare, 
probably less than 10% of ALK+ cases.
Much is yet to be learned about treatment of patients 
with both ALK+ and EGFR mutations. Although some of 
these patients have had a good response to the EGFR inhibitors 
erlotinib and gefitinib,22,23 one patient showed resistance to 
erlotinib.21 Further research is needed to determine if patients 
with coexisting EGFR mutation and ALK gene rearrangement 
may have altered response to EGFR or ALK inhibitors (i.e., 
whether blockade of one pathway will fail to result in slowed 
tumor growth because of oncogenic addiction to the other 
mutated pathway). This will be important to determine whether 
these drugs should be used in a synchronous or sequential 
fashion to achieve maximum benefit. These treatment 
issues have important clinical implications, considering 
acquired resistance to EGFR and ALK inhibitors is a known 
phenomenon.24,27,28,33 Although EGFR and ALK mutations 
have been well documented to occur within the same tumor, 
as is in our case, it is of interest whether they are occurring 
in the same cells, that is, whether the same neoplastic clone 
FIGURE 2.  Pulmonary adenocarcinoma (A, hematoxylin and eosin stain; original magnification, 200×) with acinar growth 
and signet ring cells, showing MET N375S by LuCaMSP (B) confirmed by sequencing (C). The tumor shows 3+ ALK staining by 
immunohistochemistry (D) and break-apart of the probes flanking the ALK locus by fluorescent in situ hybridization (E, arrow).
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contains both ALK and EGFR mutations, or if separate 
subclones within the tumor contain these separate oncogenic 
drivers. The ALK IHC in our case was only 1+ intensity and 
had a somewhat patchy distribution. Although confirmed by 
sequencing, we cannot determine with certainty whether these 
mutations are occurring in the same or different tumor cell 
populations.
The development of appropriate testing algorithms in 
NSCLC is a complicated and controversial issue with many 
factors to consider, including demographic information, 
tumor histology, mutation frequency, and cost of testing. The 
coexistence of EGFR and ALK mutations would be missed 
in an algorithm omitting ALK testing in tumors showing 
EGFR mutation or vice versa, which would advocate testing 
all tumors for both mutations. However, some may argue that 
the incidence of coexisting ALK and EGFR mutation is low 
enough to justify such an algorithm. One possible cost saving 
approach is screening with ALK IHC and EGFR mutational 
analysis at the same time. ALK IHC is a relatively inexpensive 
method and has been shown to correlate well with FISH.34 
Cases with any degree of ALK positivity (1+, 2+, or 3+) could 
then be sent for confirmatory testing by FISH. Alternatively, 
FIGURE 3.  Pulmonary adenocarcinoma (A, hematoxylin and eosin stain; original magnification, 200×) with cribriform and 
solid growth and signet ring cells, showing MET R988C by LuCaMSP (B) confirmed by sequencing (C). The tumor shows 3+ ALK 
staining by immunohistochemistry (D) and break-apart of the probes flanking the ALK locus by fluorescent in situ hybridization 
(E, arrow).
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ALK testing could be considered for patients with known 
EGFR mutations if they have other clinical or pathologic fea-
tures associated with ALK rearrangement (young age, signet 
ring, or mucinous cribriform histology). However, western 
lung cancer patient populations (such as those included in the 
present study) are dominated by older patients with a signifi-
cant smoking history, and such an algorithm may miss patients 
that do not fit the expected demographic. For example, while 
the age range was broad (36-87 years) and certainly included 
young patients, the average age of our ALK+ patients was 
61 years. These algorithm questions will likely become moot 
once comprehensive mutation profiling assays, and eventually, 
those based on next generation sequencing become widely 
available to assess all genes of interest in a single test.
Alterations in the MET gene have been described in lung 
cancer, including germline mutations and gene amplification, 
which has been associated with poor prognosis.35–37 We found 
point mutations in the MET gene in four of our cases, but MET 
amplification was not found in any of the 12 tested cases. 
These MET mutations are likely germline because we found 
the identical mutations in the adjacent morphologically nor-
mal lung parenchyma, and the peak height of the mutant and 
wild-type alleles were the same, a feature typical of germline 
alterations. The MET N375S mutation leads to a conservative 
amino acid substitution (asparagine to serine) involving the 
MET semaphorin domain (containing the ligand binding site). 
This mutation has been described in patients with NSCLC, 
where it has been found to be a germline alteration that is 
particularly common in patients of East Asian decent and 
likely represents a polymorphism and not a pathogenic muta-
tion.35,38–40 This mutation has also been described in cell lines of 
pulmonary small-cell carcinoma.38 It has been noted that MET 
N375S leads to altered ligand binding and less responsive-
ness to MET inhibitors in vitro.38 MET R988C is a mutation 
in the juxtamembrane domain that leads to a nonconservative 
amino acid substitution (arginine to cysteine). It is suspected 
to be pathogeneic in other tumors including small-cell car-
cinoma of the lung, where it has been described in multiple 
cell lines.39 This mutation has been associated with increased 
constitutive kinase activity associated with increased tumori-
genicity, generation of reactive oxygen species, growth factor 
independence, alteration in cell adhesion, and increased motil-
ity or migration.39,41 MET R988C mutations have also been 
described within NSCLC and in adjacent normal parenchyma, 
so this may also represent a germline mutation, although field 
effect extending into adjacent morphologically normal paren-
chyma cannot be completely excluded.38,39 On the basis of the 
1000 genomes database and a select number of normal lung 
specimens tested at Mayo Clinic (data not shown), the rela-
tive minor allele frequency for these single nucleotide poly-
morphisms is between 0.1% and 2.1% (Table 3). Although 
our numbers are small, the frequency of ALK+ cases with 
these rare MET alleles seemed to be significantly higher than 
expected (4% for each allele). Further study is needed to 
investigate the potential clinical and therapeutic importance 
of NSCLC harboring coexisting ALK and MET mutations. 
This area is especially interesting, considering that crizotinib 
also inhibits the protein encoded by the MET gene (hepatocyte 
growth factor receptor tyrosine kinase).42 Whether this might 
lead to enhanced drug effectiveness in tumors with both ALK 
and MET mutations remains to be elucidated.
It is interesting to note the detection of JAK2 V617F in 
our analysis, which raises an important point of caution when 
interpreting genetic testing in cancer. The nature of PCR-based 
genetic testing does not allow visualization of the exact cell 
containing the mutation in question. In addition, these tests are 
extremely sensitive and can detect a mutation present in only a 
small minority of cells. Although this attribute makes genetic 
testing extremely powerful, it also introduces potential issues 
of contamination and overinterpretation. In our case, the JAK2 
mutation was present in a minority of the tested DNA (7%) and 
was not confirmed by Sanger sequencing. Thoughtful review 
of the patient history revealed that the patient had essential 
thrombocythemia. Circulating hematopoetic cells present in 
the biopsy are the likely source of the JAK2 mutation, not 
the lung cancer cells. This underscores the critical evaluation 
of genetic testing results, with consideration of the mutation 
frequency and the overall clinical context.
In summary, we found a single case of EGFR muta-
tion and four cases of MET mutations among the 25 ALK+ 
lung adenocarcinoma cases screened for known mutations in 
important oncogenic driver genes. Our results will add to the 
body of evidence, which supports that approximately 4% of 
ALK+ tumors can have coexisting EGFR mutations, and also 
documents MET mutations in ALK+ lung adenocarcinomas. 
The pathogenic role of these MET mutations is not entirely 
clear and further studies are needed. Therapeutic implications 
of coexisting mutations in EGFR and MET genes might be 
important in the responsiveness to initial crizotinib treatment 
and in the development of crizotinib resistance.
ACKNOWLEDGMENTS
We thank Robert B. Diasio of the Mayo Clinic Cancer 
Center for his generous support and guidance with the use of 
the MassArray assay. The study was supported in part through 
Mayo Clinic Center for Individualized Medicine (Drs. Jin Jen 
and JinSung Jang), and the American Cancer Society New 
Investigator Award to Dr. Jin Jen.
REFERENCES
 1. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to 
histological characteristics in a subset of lung cancers. J Thorac Oncol 
2008;3:13–17.
 2. Soda M, Choi YL, Enomoto M, et al. Identification of the transform-
ing EML4-ALK fusion gene in non-small-cell lung cancer. Nature 
2007;448:561–566.
TABLE 3.  Expected Minor Allele Frequency of MET N375S 
and R988C Based on the 1000 Genomes Database and 
Study of 49 Normal Lung Specimens Tested at Mayo Clinic, 
Compared with Observed Frequency in 25 Tumors with ALK 
Rearrangement
Allele
Minor Allele Frequency
1000 Genomes 49 Mayo Normal Lung 25 ALK+
MET N375S 0.021 0 0.04
MET R988C 0.001 0.01 0.04
581Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume 8, Number 5, May 2013 EGFR and MET Mutations in ALK+ Pulmonary Adenocarcinoma
 3. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic 
features characterize ALK-rearranged lung adenocarcinoma in the west-
ern population. Clin Cancer Res 2009;15:5216–5223.
 4. Soda M, Takada S, Takeuchi K, et al. A mouse model for EML4-ALK-
positive lung cancer. Proc Natl Acad Sci USA 2008;105:19893–19897.
 5. Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK is asso-
ciated with development of lung adenocarcinomas lacking EGFR and 
KRAS mutations and is correlated with ALK expression. Mol Cancer 
2010;9:188.
 6. Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-
smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 2012;7:90–97.
 7. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase 
immunoreactivity correlates with ALK gene rearrangement and tran-
scriptional up-regulation in non-small cell lung carcinomas. Hum Pathol 
2009;40:1152–1158.
 8. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic 
analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 
2011;35:1226–1234.
 9. Yoshida A, Tsuta K, Watanabe S, et al. Frequent ALK rearrangement and 
TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell 
component. Lung Cancer 2011;72:309–315.
 10. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhi-
bition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–1703.
 11. Administration U.F.a.D. FDA approves Xalkori with companion diag-
nostic for a type of late-stage lung cancer 08-26-2011. Available from: 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm269856.htm.
 12. Koivunen JP, Mermel C, Zejnullahu K, et al. EML4-ALK fusion gene 
and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 
2008;14:4275–4283.
 13. Zhu CQ, da Cunha Santos G, Ding K, et al.; National Cancer Institute of 
Canada Clinical Trials Group Study BR.21. Role of KRAS and EGFR as 
biomarkers of response to erlotinib in National Cancer Institute of Canada 
Clinical Trials Group Study BR.21. J Clin Oncol 2008;26:4268–4275.
 14. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are 
common in lung cancers from “never smokers” and are associated with 
sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 
2004;101:13306–13311.
 15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epider-
mal growth factor receptor underlying responsiveness of non-small-cell 
lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
 16. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung can-
cer: correlation with clinical response to gefitinib therapy. Science 
2004;304:1497–1500.
 17. Kim HR, Shim HS, Chung JH, et al. Distinct clinical features and out-
comes in never-smokers with nonsmall cell lung cancer who harbor EGFR 
or KRAS mutations or ALK rearrangement. Cancer 2012;118:729–739.
 18. Xu J, He J, Yang H, et al. Somatic mutation analysis of EGFR, KRAS, 
BRAF and PIK3CA in 861 patients with non-small cell lung cancer. 
Cancer Biomark 2011;10:63–69.
 19. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance 
of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17.
 20. Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-
TKIs treatment in patients with non-small cell lung cancer: a meta-analy-
sis of 22 studies. Lung Cancer 2010;69:272–278.
 21. Tiseo M, Gelsomino F, Boggiani D, et al. EGFR and EML4-ALK gene 
mutations in NSCLC: a case report of erlotinib-resistant patient with both 
concomitant mutations. Lung Cancer 2011;71:241–243.
 22. Popat S, Vieira de Araújo A, Min T, et al. Lung adenocarcinoma with 
concurrent exon 19 EGFR mutation and ALK rearrangement responding 
to erlotinib. J Thorac Oncol 2011;6:1962–1963.
 23. Kuo YW, Wu SG, Ho CC, Shih JY. Good response to gefitinib in lung ade-
nocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR 
mutation. J Thorac Oncol 2010;5:2039–2040.
 24. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to 
crizotinib in patients with ALK gene rearranged non-small cell lung can-
cer. Clin Cancer Res 2012;18:1472–1482.
 25. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted ther-
apy and beyond. Mod Pathol 2008;21:S16–S22.
 26. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histo-
logical evolution of lung cancers acquiring resistance to EGFR inhibitors. 
Sci Transl Med 2011;3:75ra26.
 27. Zhang S, Wang F, Keats J, et al. Crizotinib-resistant mutants of EML4-
ALK identified through an accelerated mutagenesis screen. Chem Biol 
Drug Des 2011;78:999–1005.
 28. Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired 
crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 
2012;4:120ra17.
 29. Yi ES, Boland JM, Maleszewski JJ, et al. Correlation of IHC and FISH 
for ALK gene rearrangement in non-small cell lung carcinoma: IHC 
score algorithm for FISH. J Thorac Oncol 2011;6:459–465.
 30. Thomas RK, Baker AC, Debiasi RM, et al. High-throughput oncogene 
mutation profiling in human cancer. Nat Genet 2007;39:347–351.
 31. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of 
the EML4-ALK transforming gene in non-small cell lung cancer. Cancer 
Res 2008;68:4971–4976.
 32. Shinmura K, Kageyama S, Igarashi H, et al. EML4-ALK fusion tran-
scripts in immunohistochemically ALK-positive non-small cell lung car-
cinomas. Exp Ther Med 2010;1:271–275.
 33. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and 
resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 
2005;352:786–792.
 34. Yi ES, Chung JH, Kulig K, Kerr KM. Detection of anaplastic lymphoma 
kinase (ALK) gene rearrangement in non-small cell lung cancer and 
related issues in ALK inhibitor therapy: a literature review. Mol Diagn 
Ther 2012;16:143–150.
 35. Okuda K, Sasaki H, Yukiue H, Yano M, Fujii Y. Met gene copy number 
predicts the prognosis for completely resected non-small cell lung cancer. 
Cancer Sci 2008;99:2280–2285.
 36. Tsuta K, Kozu Y, Mimae T, et al. c-MET/phospho-MET protein expres-
sion and MET gene copy number in non-small cell lung carcinomas. J 
Thorac Oncol 2012;7:331–339.
 37. Dziadziuszko R, Wynes MW, Singh S, et al. Correlation between MET 
gene copy number by silver in situ hybridization and protein expression 
by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 
2012;7:340–347.
 38. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and 
functional analysis of MET mutations in lung cancer. Clin Cancer Res 
2009;15:5714–5723.
 39. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small 
cell lung cancer: novel juxtamembrane domain mutations regulating cyto-
skeletal functions. Cancer Res 2003;63:6272–6281.
 40. Tengs T, Lee JC, Paez JG, et al. A transforming MET mutation discov-
ered in non-small cell lung cancer using microarray-based resequencing. 
Cancer Lett 2006;239:227–233.
 41. Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R. Activation of 
HGF/c-Met pathway contributes to the reactive oxygen species genera-
tion and motility of small cell lung cancer cells. Am J Physiol Lung Cell 
Mol Physiol 2007;292:L1488–L1494.
 42. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor 
activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase 
and c-Met, in experimental models of anaplastic large-cell lymphoma. 
Mol Cancer Ther 2007;6:3314–3322.
